Condensed Statements of Operations (Unaudited)(Current Period) (USD $)	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Revenue:
Product Sales		$ 646,147
Royalties	84,960	348,744
Licensing Revenue	262,689	262,689
Development Fees and Other	203,573	165,628
Tarsa Revenue	62,550	328,075
Total Revenue	613,772	1,751,283
Operating Expenses:
Research and Development	850,518	1,258,659
Cost of Goods Sold	1,635,818	246,357
General and Administrative	1,975,187	2,093,172
Unallocated Facility Expenses	529,250	859,113
Asset Impairment Charges	983,990	55,000
Total Operating Expenses	5,974,763	4,457,301
Operating Loss	(5,360,991)	(2,706,018)
Other Income (Expense):
Interest and Other Income	10,538	80,433
Interest Expense	(4,520,883)	(2,867,002)
Change in fair value of embedded derivative	11,850,000	2,920,000
Loss on Investment in Tarsa		(650,571)
Income (Loss) Before Income Taxes	1,978,664	(3,223,158)
Income Tax Benefit		26,757
Net Income (Loss)	$ 1,978,664	$ (3,196,401)
Net Income (Loss) Per Share:
Basic (in Dollars per share)	$ 0.02	$ (0.03)
Diluted (in Dollars per share)	$ (0.01)	$ (0.03)
Weighted Average Number of Shares Outstanding:
Basic (in Shares)	95,950,234	95,314,825
Diluted (in Shares)	507,998,045	95,314,825